The US Food and Drug Administration (FDA) has officially authorized the use of Tzield (teplizumab-mzwv) to postpone the onset of clinical stage 3 type 1 diabetes in children as young as 12 months who are currently at stage 2. This regulatory update lowers the minimum age requirement, which was previously set at eight years.
The authorization follows data from the PETITE-T1D Phase IV clinical trial, a study involving 23 participants under the age of eight. The research focused on the medication’s safety profile and metabolic processing within younger pediatric patients. During the trial, subjects underwent a 14-day regimen of daily intravenous administrations. The findings suggest that early pharmacological intervention can effectively modulate the immune response, thereby preserving the function of insulin-generating cells in the pancreas for a longer period.
Beyond the United States, this biological therapy has gained regulatory clearance in several regions, including the European Union, the United Kingdom, Canada, China, and various Middle Eastern nations. Additionally, health authorities are evaluating the drug’s effectiveness for patients already at stage 3 to slow down further biological deterioration. Type 1 diabetes is characterized by a four-stage autoimmune progression that eventually destroys the body’s ability to produce insulin. Extending treatment eligibility to younger children aims to alter the disease’s natural course and alleviate the long-term healthcare burden on families.
Source: https://www.pharmaceutical-technology.com/news/sanofi-fda-approval-tzield/?cf-view